The pandemic has shown and confirmed the weaknesses of our companies and our economy in many areas.
With a re-industrialization and an attractiveness mindset, the French government has decided to support the relocalization of production capacity through a call for projects. This financial support is focused on projects deemed strategic for the French economy, mainly in the fields of health, food and electronics.
Health industry wise, one of the first projects supported is the Aguettant pharmaceutical laboratory project. This independent and family-owned pharmaceutical company is leading the hospital injectable drugs market. One of its main technologies is the ready-to-use syringe, which reduces the risk for patients of medication errors.
Aguettant pharmaceutical laboratory plans to expand its production of “100% made in France” ready-to-use products with the launch a new filling line and also plans to develop its portfolio of injectable products.
The objective is to be able to provide the French market with more so-called “essential” medicines.
Cebiphar has been selected by Aguettant pharmaceutical laboratory to provide analytical support (development, method validation and stability studies of pilot batches) in order to contribute to the acceleration of the development of 4 essential injectable products.